智飞生物(300122) - 2017 Q2 - 季度业绩预告

Financial Performance - The company expects a net profit attributable to shareholders of 156.51 million to 192.62 million CNY, representing an increase of 1200% to 1500% compared to the same period last year[2] - The company anticipates that the net profit, excluding non-recurring gains and losses, will also rise by 1200% to 1500%[5] Factors Influencing Profit - The significant profit increase is attributed to the recovery of vaccine sales following the resolution of uncertainties from the "3.18" vaccine industry incident[4] - The company has successfully implemented its annual business plan, leading to substantial growth in main business revenue and net profit[4] Future Reporting - The financial data for the first half of 2017 will be detailed in the company's upcoming half-year report[5]